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1. Purpose of the advisory panel and background
The purpose of this protocol is to set out the aims, objectives and commitments of the second
phase of the James Lind Alliance (JLA) Priority Setting Partnership (PSP).in Cystic Fibrosis (CF)
and the basic roles and responsibilities of the partners therein.
The James Lind Alliance Priority Setting Partnership PSP (JLA PSP) in cystic fibrosis (CF) has used
a robust and widely accepted methodology to develop the top 10 questions for clinical research in
CF, through discussions with both the clinical and patient community1. The top ten priorities are
available on the James Lind Alliance website2.
We believe that this represents an important step towards “co-production” of clinical research, so
that the conception, delivery and dissemination of research are each conducted in partnership with
the patient community3. However, a number of the questions in the JLA PSP top 10 are very broad
and do not lend themselves to being transformed into a testable hypothesis for a clinical trial or
other clinical research study. Indeed, some of the top 10 questions may give rise to several clinical
studies. We believe there is a need to have an ongoing conversation with the CF community (both
lay and professional) in order to gain a deeper understanding of what JLA PSP participants
understand by the top 10 research questions and to design the research studies which meet their
needs. Four of the top 10 questions stand out as requiring further discussion.
What are the effective ways of simplifying the treatment burden of people with Cystic
Fibrosis? (Q1)
How can we relieve gastro-intestinal (GI) symptoms, such as stomach pain, bloating and
nausea in people with Cystic Fibrosis? (Q2)
What effective ways of motivation, support and technologies help people with Cystic
Fibrosis improve and sustain adherence to treatment? (Q6)
Can exercise replace chest physiotherapy for people with Cystic Fibrosis? (Q7)
Other questions in the top 10 could be formulated into testable hypotheses more readily and a
specific study design then explored with the patient community.
2. Aims and objectives
We aim to set up an advisory panel representative of the whole CF community (lay and
professional) to allow us to explore the four questions above and develop them into a series of
testable hypotheses for clinical research. Where the hypothesis will be tested in a clinical trial, we
will develop a PICO question for each hypothesis (Population, Intervention, Comparator &
Outcome).
The objectives of the @questionCF advisory panel are to:
 work with people with CF, their family and friends, and clinicians to gain a deeper
understanding of what JLA PSP participants understand by four of the top 10 research
questions
 produce testable hypotheses for research studies which meet the needs of the CF
community.
3. The Steering Group
The @questionCF advisory panel will be led and managed by the following:
Patient representative/s:
 Zoe Elliott (Parent of children with CF)
 Oli Rayner (pwCF)
 Katie Gathercole (pwCF)
Clinical representative/s:
 Alan Smyth (Respiratory Paediatrician)
 Tracey Daniels (CF Physiotherapist)
 Ed Nash (adult respiratory physician)
 Alistair Duff (psychologist)
 Sarah Collins (dietician)
 Suja Chandran (social worker)
 Patrick Wilson (pharmacist)
 Matt Hurley (consultant respiratory paediatrician)
 Michelle Tabberner (CF Nurse)
The project will be supported and guided by:
 University of Nottingham
o Sherie Smith (Project coordinator)
o Nicola Rowbotham (Academic Clinical Fellow)
o Paul Leighton (Qualitative Researcher)
 Sophie Herbert (F1 junior doctor with interest in research)
 CF Trust
o Keith Brownlee (Director of Impact)
o Lorna Allen (Patient and Public Involvement Co-ordinator)
The Steering Group includes representation from lay and professional groups. The Steering Group
will agree the resources, including time and expertise that they will be able to contribute to each
stage of the process.
4. The wider Contributors
Organisations and individuals will be invited to be involved with this phase of the project as
contributors. Contributors are groups or individuals who agree to take part in the online surveys and
who will then be invited to participate more fully by joining our advisory panel as members. Advisory
panel members will be involved in the design of and participation in the focus groups for more
detailed analysis of the priorities. Contributors represent the following groups:
 people who have CF
 family and friends of people who have CF
 medical doctors, nurses and professionals allied to medicine with clinical experience of treating
CF.
We will work with others who are undertaking activity in this field – both identifying research
priorities, with the patient community and disseminating research findings to the community.
 The UK Cystic Fibrosis Trust – the “Insight” survey, distributed by the CF Trust, asked about
all aspects of living with CF and received over 1000 responses in the last year.
 The US CF Foundation, whose similarly named “Insight” programme seeks to identify
research questions which can be answered through the US CF Registry.
https://www.cff.org/Get-Involved/Community/Contribute-to-Our-Research/
 The Journal of Cystic Fibrosis, who produce “CF Research News” – lay summaries of
research papers.
5. The methods we will use
The majority of the project will be carried out using online methods to avoid the risk of cross-
infection from face to face work and to maximise the reach of the surveys. We will work through the
following steps.
Step 1: Identification and invitation of potential partners
Potential partner organisations will be identified through a process of peer knowledge and
consultation, through the Steering Group members’ networks. Potential partners will be contacted
and informed of the establishment and aims of the @questionCF.
Step 2: Initial steering group meeting / awareness raising
The initial steering group meeting / awareness raising will have several key objectives:
 to welcome and introduce potential members of the @questionCF2 steering group & advisory
panel
 to present the proposed plan for the @questionCF2 project
 to initiate discussion, answer questions and address concerns
 to identify those potential partner organisations which will commit to the @questionCF advisory
panel and identify individuals who will be those organisations’ representatives and the
@questionCF advisory panel’s principal contacts
 to establish principles upon which an open, inclusive and transparent mechanism can be based
for contributing to, reporting and recording the work and progress of the @questionCF advisory
panel.
 We will hold three further steering group meetings over the course of the project to guide the
process.
Step 3: Launching the project and dissemination of surveys
We will approach participants who gave us their contact details as part of the JLA PSP in CF and
we will invite them to join the @question CF advisory panel. We will also publicise this engagement
work via Twitter, other social media and via our website in order to open up participation to the
whole CF community. Participants will be asked to complete an intial online survey (priority one) and
asked if they would like to continue supporting our research by joining our advisory panel..
Step 4: Exploring and clarifying the research question
Two initial questionnaires, for each of the four priorities, will be launched sequentially over a period
of twelve months in total – one targeted at people with CF and parents of people with CF and the
other at CF health care professionals, to explore thoughts, wants and needs around each of the four
research priorities mentioned above.
 The survey content will be guided by the original questions submitted during the PSP that
fed into the final priorities.
 We will use the online survey tool SurveyMonkey® to distribute the questionnaires and
responses will be anonymous.
 We will analyse the data from the surveys in MS Excel to look for themes emerging which
can be taken forward into focus groups for more detailed discussion. The process of
deciding what to take forward will be agreed by the steering group.
 At this stage participants will be invited to express their interest in taking part in a focus
group to further refine the questions after the surveys close.
 Surveys will be designed and managed by Nicola Rowbotham and Sherie Smith with input
from the Steering group.
Step 5: Refining priorities into ‘PICO’ research questions
Step 4 will produce clinical trial ideas. These raw ideas will be assembled, categorised and refined
by Sherie Smith and Nicola Rowbotham and taken to the advisory panel. Together, the research
team and the advisory panel will generate a focus group agenda from the themes that emerge.
A focus group for each of the four priorities will be attended by both lay and professional members of
the CF community to discuss the ideas generated in greater depth. Where the hypothesis could be
tested in a clinical trial, we will develop a PICO for each hypothesis (Population, Intervention,
Comparator & Outcome).
Focus groups
 We will aim to recruit eight to ten members of the advisory panel to participate in a given focus
group
 We will run one focus group for each of the research priorities we are investigating (n = 5)
 We will ensure that the group is representative of lay and professional members
 The discussion guide will be generated from the results of the surveys.
 At least one of the research team will facilitate the focus groups which will be run using online
meeting software (BlueJeans®).
 The discussion will be recorded via the online meeting software.
Step 6: Finalisation of PICO questions by @questionCF advisory panel
The aim of the final stage is to prioritise through consensus the identified PICO questions relating to
the CF research priority. This will be occur through a final online prioritisation survey open to all
members of the @questionCF advisory panel. A modified dephi process will be used, utilising Likert
scales to enable participants to rank the trial questions in order of priority.
6. Dissemination of findings and research
Findings and research
It is anticipated that the findings of the @questionCF advisory panel will be reported to funding and
research agenda setting organisations such as the NIHR and the major research funding charities.
Steering Group members and partners are expected to develop the findings into clinical research
plans to use when approaching potential funders, or when allocating funding for research
themselves, if applicable.
Publicity
As well as alerting funders, partners and Steering Group members are encouraged to publish the
findings of the @questionCF advisory panel using both internal and external communication
mechanisms. The findings will be written up in at least one journal paper (potential publishers
including Thorax and Journal of Cystic Fibrosis). We will also present findings at the European and
North American Cystic Fibrosis conferences. As with all our work we will keep the CF Community
informed of our findings through online lay accessible infographics, blogs and vlogs (video media).
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